Dr Reddy's Buyback Plan Signals Pipeline Belief?
This article was originally published in Scrip
Executive Summary
Shares in Dr Reddy's Laboratories continued their upward trend on Feb. 18, the second day on the trot, after the company said that it planned to buyback equity for an aggregate sum not exceeding INR15.69bn ($229m).